
IndraLab
Statements
reach
"In the 4T1 mammary carcinoma model, we have shown that B/I selectively activates CD62L - or sensitized T cells and that the anti-tumor activity resides in the CD62L - fraction of lymphocytes obtained from donor lymph nodes; only the CD62L - subset proliferates after B/I activation and has anti-tumor activity [XREF_BIBR]."
reach
"Unsorted B/I activated lymphocytes, CD62L + cells that remained CD62L + after B/I and expansion (CD62L + --> CD62L +), CD62L + cells that downregulated CD62L after B/I treatment and expansion (CD62L + --> CD62L -), CD62L - cells that remained CD62L - after B/I treatment and expansion (CD62L - --> CD62L -), or CD62L - cells that upregulated CD62L expression after B/I and expansion (CD62L - --> CD62L +) were infused into CYP pre-treated tumor bearing mice."